Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.8K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

522
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
522
Hepatic Portal System01:21

Hepatic Portal System

4.5K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
4.5K
Subviral Agents01:29

Subviral Agents

355
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
355
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

6.7K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026
Same author

Outcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria-A Single-center Experience.

Transplantation direct·2026
Same author

Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration.

Cancers·2026
Same author

Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.

medRxiv : the preprint server for health sciences·2025
Same author

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.

Cancers·2024
Same author

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.

Molecular cancer therapeutics·2024
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Dec 10, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Hepatitis C Virus.

David E Kaplan1

  • 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (D.E.K.).

Annals of Internal Medicine
|September 1, 2020
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) infection affects millions in the US, but new treatments offer a cure. Expanding access, especially for people who inject drugs, and involving primary care are key to eradicating this bloodborne pathogen.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.5K

Related Experiment Videos

Last Updated: Dec 10, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.5K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis C virus (HCV) is a prevalent bloodborne pathogen in the United States, with approximately 2.4 million individuals chronically infected.
  • A significant portion of those infected remain unaware of their condition, highlighting a critical gap in diagnosis and care.
  • Despite the high prevalence, highly effective and well-tolerated therapies with simplified treatment protocols are now available.

Purpose of the Study:

  • To emphasize the national goal of eradicating Hepatitis C virus (HCV).
  • To highlight the necessity of expanding treatment access to hard-to-reach populations, including persons who inject drugs.
  • To underscore the crucial role of primary care providers in managing HCV, from screening to treatment.

Main Methods:

  • Review of current HCV treatment landscape and epidemiological data.
  • Analysis of treatment access barriers for key populations.
  • Assessment of the potential impact of primary care integration in HCV management.

Main Results:

  • Highly effective and well-tolerated therapies for HCV are readily available.
  • Simplified treatment algorithms are now in place, facilitating broader application.
  • Eradication of HCV is a stated national objective.

Conclusions:

  • Achieving HCV eradication necessitates increased access to treatment for all populations, particularly persons who inject drugs.
  • Primary care providers are essential for screening, stratifying patients, and administering treatment to combat the HCV burden.
  • Addressing the significant disease burden requires a comprehensive strategy involving expanded screening and treatment initiatives.